SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences gets post application action letter for cGMP, PAI at Ahmedabad facility

07 Mar 2024 Evaluate

Zydus Lifesciences has received Post Application Action Letter from the USFDA for the inspection conducted at the Ahmedabad API facility of the company, confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. 

This facility underwent for-cause cGMP surveillance and Pre-Approval Inspection for manufacturing of drug substances Enzalutamide from December 14 to 22, 2023.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

923.10 7.65 (0.84%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×